PPARγ activation inhibits cerebral arteriogenesis in the hypoperfused rat brain

Acta Physiologica

Volumn 210, Issue 2, 2014, Pages 354-368

  Duelsner, A ^a   Gatzke, N ^a   Hillmeister, P ^a   Glaser, J ^a   Zietzer, A ^a   Nagorka, S ^a   Janke, D ^b,c   Pfitzner, J ^a   Stawowy, P ^d   Meyborg, H ^d   Urban, D ^d   Bondke Persson, A ^b   Buschmann, I R ^a  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Arteriogenesis; Blood flow; Collateral growth; Glitazone; PPAR

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; METFORMIN; METHYLCELLULOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SITAGLIPTIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOGENIC FACTOR;

ANGIOGENESIS; ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN PERFUSION; CANCER INHIBITION; CARDIOVASCULAR RISK; CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SWELLING; CEREBRAL ARTERIOGENESIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHYSIOLOGICAL PROCESS; POST MORTEM LATEX ANGIOGRAPHY; POSTERIOR CEREBRAL ARTERY; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT; ANIMAL; BRAIN; BRAIN ISCHEMIA; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODYNAMICS; MALE; METABOLISM; PATHOPHYSIOLOGY; VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOTTING, WESTERN; BRAIN; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMODYNAMICS; HUMANS; MALE; MYOCYTES, SMOOTH MUSCLE; NEOVASCULARIZATION, PHYSIOLOGIC; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 84892436448     PISSN: 17481708     EISSN: 17481716     Source Type: Journal    
DOI: 10.1111/apha.12179     Document Type: Article

References (88)

1. Aljabri, M.B., Songstad, N.T., Lund, T., Serrano, M.C., Andreasen, T.V., Al-Saad, S., Lindal, S., Sitras, V., Acharya, G. & Ytrehus, K. 2011. Pregnancy protects against antiangiogenic and fibrogenic effects of angiotensin II in rat hearts. Acta Physiol (Oxf) 201, 445-456.
2. Aljada, A., O'Connor, L., Fu, Y.Y. & Mousa, S.A. 2008. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 11, 361-367.
3. Asano, M., Nakajima, T., Iwasawa, K., Morita, T., Nakamura, F., Imuta, H., Chisaki, K., Yamada, N., Omata, M. & Okuda, Y. 1999. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells. Br J Pharmacol 128, 673-683.
4. Balakumar, P. & Kathuria, S. 2012. Submaximal PPARgamma activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders. Br J Pharmacol 166, 1981-1992.
5. Bergmann, C.E., Hoefer, I.E., Meder, B., Roth, H., van Royen, N., Breit, S.M., Jost, M.M., Aharinejad, S., Hartmann, S. & Buschmann, I.R. 2006. Arteriogenesis depends on circulating monocytes and macrophage accumulation and is severely depressed in op/op mice. J Leukoc Biol 80, 59-65.
6. Bisschops, R.H., Klijn, C.J., Kappelle, L.J., van Huffelen, A.C. & van der Grond, J. 2003. Collateral flow and ischemic brain lesions in patients with unilateral carotid artery occlusion. Neurology 60, 1435-1441.
7. Busch, H.J., Buschmann, I.R., Mies, G., Bode, C. & Hossmann, K.A. 2003. Arteriogenesis in hypoperfused rat brain. J Cereb Blood Flow Metab 23, 621-628.
8. Buschmann, I., Heil, M., Jost, M. & Schaper, W. 2003. Influence of inflammatory cytokines on arteriogenesis. Microcirculation 10, 371-379.
9. Byts, N., Samoylenko, A., Woldt, H., Ehrenreich, H. & Siren, A.L. 2006. Cell type specific signalling by hematopoietic growth factors in neural cells. Neurochem Res 31, 1219-1230.
10. Cai, W.J., Kocsis, E., Wu, X., Rodriguez, M., Luo, X., Schaper, W. & Schaper, J. 2004. Remodeling of the vascular tunica media is essential for development of collateral vessels in the canine heart. Mol Cell Biochem 264, 201-210.
11. Carrao, A.C., Chilian, W.M., Yun, J., Kolz, C., Rocic, P., Lehmann, K., van den Wijngaard, J.P., van Horssen, P., Spaan, J.A., Ohanyan, V., Pung, Y.F. & Buschmann, I. 2009. Stimulation of coronary collateral growth by granulocyte stimulating factor: role of reactive oxygen species. Arterioscler Thromb Vasc Biol 29, 1817-1822.
12. Chacko, B.K., Scott, D.W., Chandler, R.T. & Patel, R.P. 2011. Endothelial surface N-glycans mediate monocyte adhesion and are targets for anti-inflammatory effects of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem 286, 38738-38747.
13. Deindl, E. 2007. Arteriogenesis: a focus on signal transduction cascades and transcription factors. Thromb Haemost 98, 940-943.
14. Deindl, E., Zaruba, M.M., Brunner, S., Huber, B., Mehl, U., Assmann, G., Hoefer, I.E., Mueller-Hoecker, J. & Franz, W.M. 2006. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 20, 956-958.
15. Dodd, T., Jadhav, R., Wiggins, L., Stewart, J., Smith, E., Russell, J.C. & Rocic, P. 2011. MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK. J Mol Cell Cardiol 51, 1015-1025.
16. Duelsner, A., Gatzke, N., Glaser, J., Hillmeister, P., Li, M., Lee, E.J., Lehmann, K., Urban, D., Meyborg, H., Stawowy, P., Busjahn, A., Nagorka, S., Bondke Persson, A. & Buschmann, I.R. 2012a. Granulocyte colony-stimulating factor improves cerebrovascular reserve capacity by enhancing collateral growth in the circle of willis. Cerebrovasc Dis 33, 419-429.
17. Duelsner, A., Gatzke, N., Glaser, J., Hillmeister, P., Li, M., Lee, E.J., Lehmann, K., Urban, D., Meyborg, H., Stawowy, P., Busjahn, A., Nagorka, S., Persson, A.B. & Buschmann, I.R. 2012b. Acetylsalicylic acid, but not clopidogrel, inhibits therapeutically induced cerebral arteriogenesis in the hypoperfused rat brain. J Cereb Blood Flow Metab 32, 105-114.
18. Epstein, S.E., Stabile, E., Kinnaird, T., Lee, C.W., Clavijo, L. & Burnett, M.S. 2004. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 109, 2826-2831.
19. Fischer, A.H., Jacobson, K.A., Rose, J. & Zeller, R. 2008. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc 2008, pdb prot4986.
20. Forst, T., Pfutzner, A., Lubben, G., Weber, M., Marx, N., Karagiannis, E., Koehler, C., Baurecht, W., Hohberg, C. & Hanefeld, M. 2007. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 56, 491-496.
21. Friedland, S.N., Leong, A., Filion, K.B., Genest, J., Lega, I.C., Mottillo, S., Poirier, P., Reoch, J. & Eisenberg, M.J. 2012. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med 125, 126-133.
22. Game, B.A., Maldonado, A., He, L. & Huang, Y. 2005. Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism. Atherosclerosis 178, 249-256.
23. Geldmacher, D.S., Fritsch, T., McClendon, M.J. & Landreth, G. 2011. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68, 45-50.
24. Ghosh, S.S., Gehr, T.W., Ghosh, S., Fakhry, I., Sica, D.A., Lyall, V. & Schoolwerth, A.C. 2003. PPARgamma ligand attenuates PDGF-induced mesangial cell proliferation: role of MAP kinase. Kidney Int 64, 52-62.
25. Goetze, S., Kintscher, U., Kim, S., Meehan, W.P., Kaneshiro, K., Collins, A.R., Fleck, E., Hsueh, W.A. & Law, R.E. 2001. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration. J Cardiovasc Pharmacol 38, 909-921.
26. Goetze, S., Bungenstock, A., Czupalla, C., Eilers, F., Stawowy, P., Kintscher, U., Spencer-Hansch, C., Graf, K., Nurnberg, B., Law, R.E., Fleck, E. & Grafe, M. 2002. Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 40, 748-754.
27. de Groot, D., Pasterkamp, G. & Hoefer, I.E. 2009. Cardiovascular risk factors and collateral artery formation. Eur J Clin Invest 39, 1036-1047.
28. Grundmann, S., Piek, J.J., Pasterkamp, G. & Hoefer, I.E. 2007. Arteriogenesis: basic mechanisms and therapeutic stimulation. Eur J Clin Invest 37, 755-766.
29. Hamblin, M., Chang, L., Zhang, H., Yang, K., Zhang, J. & Chen, Y.E. 2011. Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma mediates pioglitazone-reduced vascular lesion formation. Arterioscler Thromb Vasc Biol 31, 352-359.
30. Han, S.J., Hur, K.Y., Kim, Y.S., Kang, E.S., Kim, S.I., Kim, M.S., Kwak, J.Y., Kim, D.J., Choi, S.H., Cha, B.S. & Lee, H.C. 2010. Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. Nephrol Dial Transplant 25, 976-984.
31. Hattori, Y., Akimoto, K. & Kasai, K. 2000. The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun 273, 1144-1149.
32. Heil, M., Ziegelhoeffer, T., Pipp, F., Kostin, S., Martin, S., Clauss, M. & Schaper, W. 2002. Blood monocyte concentration is critical for enhancement of collateral artery growth. Am J Physiol Heart Circ Physiol 283, H2411-H2419.
33. Hendrikse, J., Hartkamp, M.J., Hillen, B., Mali, W.P. & van der Grond, J. 2001. Collateral ability of the circle of Willis in patients with unilateral internal carotid artery occlusion: border zone infarcts and clinical symptoms. Stroke 32, 2768-2773.
34. Hillmeister, P. & Persson, P.B. 2012. The Kallikrein-Kinin system. Acta Physiol (Oxf) 206, 215-219.
35. Hillmeister, P., Lehmann, K.E., Bondke, A., Witt, H., Duelsner, A., Gruber, C., Busch, H.J., Jankowski, J., Ruiz-Noppinger, P., Hossmann, K.A. & Buschmann, I.R. 2008. Induction of cerebral arteriogenesis leads to early-phase expression of protease inhibitors in growing collaterals of the brain. J Cereb Blood Flow Metab 28, 1811-1823.
36. Hillmeister, P., Gatzke, N., Dulsner, A., Bader, M., Schadock, I., Hoefer, I., Hamann, I., Infante-Duarte, C., Jung, G., Troidl, K. et al. 2011. Arteriogenesis is modulated by bradykinin receptor signaling. Circ Res 109, 524-533.
37. Hoefer, I.E., Grundmann, S., Schirmer, S., van Royen, N., Meder, B., Bode, C., Piek, J.J. & Buschmann, I.R. 2005a. Aspirin, but not clopidogrel, reduces collateral conductance in a rabbit model of femoral artery occlusion. J Am Coll Cardiol 46, 994-1001.
38. Hoefer, I.E., Grundmann, S., van Royen, N., Voskuil, M., Schirmer, S.H., Ulusans, S., Bode, C., Buschmann, I.R. & Piek, J.J. 2005b. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. Atherosclerosis 181, 285-293.
39. Hong, S.J., Kim, S.T., Kim, T.J., Kim, E.O., Ahn, C.M., Park, J.H., Kim, J.S., Lee, K.M. & Lim, D.S. 2010. Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation. Arterioscler Thromb Vasc Biol 30, 2655-2665.
40. Hossmann, K.A. & Buschmann, I.R. 2005. Granulocyte-macrophage colony-stimulating factor as an arteriogenic factor in the treatment of ischaemic stroke. Expert Opin Biol Ther 5, 1547-1556.
41. Hsueh, W.A. 2001. PPAR-gamma effects on the vasculature. J Investig Med 49, 127-129.
42. Hu, H., Zou, C., Xi, X., Shi, Z., Wang, G. & Huang, X. 2012. Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. J Surg Res 178, 460-465.
43. Ji, H., Wang, H., Zhang, F., Li, X., Xiang, L. & Aiguo, S. 2010. PPARgamma agonist pioglitazone inhibits microglia inflammation by blocking p38 mitogen-activated protein kinase signaling pathways. Inflamm Res 59, 921-929.
44. Joner, M., Farb, A., Cheng, Q., Finn, A.V., Acampado, E., Burke, A.P., Skorija, K., Creighton, W., Kolodgie, F.D., Gold, H.K. & Virmani, R. 2007. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27, 182-189.
45. Kanlop, N., Thommasorn, S., Palee, S., Weerateerangkul, P., Suwansirikul, S., Chattipakorn, S. & Chattipakorn, N. 2011. Granulocyte colony-stimulating factor stabilizes cardiac electrophysiology and decreases infarct size during cardiac ischaemic/reperfusion in swine. Acta Physiol (Oxf) 202, 11-20.
46. Kappert, K., Meyborg, H., Clemenz, M., Graf, K., Fleck, E., Kintscher, U. & Stawowy, P. 2008. Insulin facilitates monocyte migration: a possible link to tissue inflammation in insulin-resistance. Biochem Biophys Res Commun 365, 503-508.
47. Li, Y., Xie, Q.H., You, H.Z., Tian, J., Hao, C.M., Lin, S.Y. & Zhu, T.Y. 2012. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients-a randomized crossover trial. Perit Dial Int 32, 507-515.
48. Love, R. 2003. GM-CSF induced arteriogenesis: a potential treatment for stroke? Lancet Neurol 2, 458.
49. McCracken, J.S., Burger, P.C. & Klintworth, G.K. 1979. Morphologic observations on experimental corneal vascularization in the rat. Lab Invest 41, 519-530.
50. Mizoguchi, M., Tahara, N., Tahara, A., Nitta, Y., Kodama, N., Oba, T., Mawatari, K., Yasukawa, H., Kaida, H., Ishibashi, M., Hayabuchi, N., Harada, H., Ikeda, H., Yamagishi, S. & Imaizumi, T. 2011. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 4, 1110-1118.
51. Molavi, B., Chen, J. & Mehta, J.L. 2006. Cardioprotective effects of rosiglitazone are associated with selective overexpression of type 2 angiotensin receptors and inhibition of p42/44 MAPK. Am J Physiol Heart Circ Physiol 291, H687-H693.
52. Mouquet, F., Cuilleret, F., Susen, S., Sautiere, K., Marboeuf, P., Ennezat, P.V., McFadden, E., Pigny, P., Richard, F., Hennache, B., Vantyghem, M.C., Bertrand, M., Dallongeville, J., Jude, B. & Van Belle, E. 2009. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 30, 840-849.
53. Nagahama, R., Matoba, T., Nakano, K., Kim-Mitsuyama, S., Sunagawa, K. & Egashira, K. 2012. Nanoparticle-mediated delivery of pioglitazone enhances therapeutic neovascularization in a murine model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 32, 2427-2434.
54. Narravula, S. & Colgan, S.P. 2001. Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia. J Immunol 166, 7543-7548.
55. Papanas, N. & Maltezos, E. 2009. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 15, 3179-3192.
56. Persson, P.B. & Henriksson, J. 2011. Good publication practise in physiology. Acta Physiol 203, 403-407.
57. Persson, A.B. & Persson, P.B. 2012. Let 'em grow: the Yin and Yang of vessel growth. Acta Physiol (Oxf) 204, 466-468.
58. Rehman, J. 2008. An inconvenient truth: recognizing individual differences in arteriogenesis. Circ Res 102, 1146-1147.
59. Rocic, P. 2012. Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome? Vascul Pharmacol 57, 179-186.
60. Sakamoto, A., Hongo, M., Saito, K., Nagai, R. & Ishizaka, N. 2012. Reduction of renal lipid content and proteinuria by a PPAR-gamma agonist in a rat model of angiotensin II-induced hypertension. Eur J Pharmacol 682, 131-136.
61. Sanz, M.J., Albertos, F., Otero, E., Juez, M., Morcillo, E.J. & Piqueras, L. 2012. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-gamma activation. J Immunol 189, 411-424.
62. Schaper, W. 2009. Collateral circulation: past and present. Basic Res Cardiol 104, 5-21.
63. Schaper, W. & Schaper, J. 2004. Arteriogenesis. Springer, Amsterdam.
64. Schaper, W. & Scholz, D. 2003. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 23, 1143-1151.
65. Schierling, W., Troidl, K., Troidl, C., Schmitz-Rixen, T., Schaper, W. & Eitenmuller, I.K. 2009. The role of angiogenic growth factors in arteriogenesis. J Vasc Res 46, 365-374.
66. Schierling, W., Troidl, K., Apfelbeck, H., Troidl, C., Kasprzak, P.M., Schaper, W. & Schmitz-Rixen, T. 2011. Cerebral arteriogenesis is enhanced by pharmacological as well as fluid-shear-stress activation of the Trpv4 calcium channel. Eur J Vasc Endovasc Surg 41, 589-596.
67. Schneeloch, E., Mies, G., Busch, H.J., Buschmann, I.R. & Hossmann, K.A. 2004. Granulocyte-macrophage colony-stimulating factor-induced arteriogenesis reduces energy failure in hemodynamic stroke. Proc Natl Acad Sci U S A 101, 12730-12735.
68. Schneider, F., Vossler, S., Franke, S., Bar, F. & Konrad, T. 2009. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension. Int J Clin Pharmacol Ther 47, 311-320.
69. Scholz, D., Ito, W., Fleming, I., Deindl, E., Sauer, A., Wiesnet, M., Busse, R., Schaper, J. & Schaper, W. 2000. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch 436, 257-270.
70. Shen, X., Li, H., Li, W., Wu, X. & Ding, X. 2012. Pioglitazone prevents hyperglycemia induced decrease of AdipoR1 and AdipoR2 in coronary arteries and coronary VSMCs. Mol Cell Endocrinol 363, 27-35.
71. Sheu, W.H., Ou, H.C., Chou, F.P., Lin, T.M. & Yang, C.H. 2006. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci 78, 1520-1528.
72. Stahl, A., Sapieha, P., Connor, K.M., Sangiovanni, J.P., Chen, J., Aderman, C.M., Willett, K.L., Krah, N.M., Dennison, R.J., Seaward, M.R., Guerin, K.I., Hua, J. & Smith, L.E. 2010. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res 107, 495-500.
73. Staniloae, C., Mandadi, V., Kurian, D., Coppola, J., Bernaski, E., El-Khally, Z., Morlote, M., Pinassi, E. & Ambrose, J. 2007. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 108, 164-169.
74. Straus, D.S., Pascual, G., Li, M., Welch, J.S., Ricote, M., Hsiang, C.H., Sengchanthalangsy, L.L., Ghosh, G. & Glass, C.K. 2000. 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci U S A 97, 4844-4849.
75. Sugiyama, Y., Yagita, Y., Oyama, N., Terasaki, Y., Omura-Matsuoka, E., Sasaki, T. & Kitagawa, K. 2011. Granulocyte colony-stimulating factor enhances arteriogenesis and ameliorates cerebral damage in a mouse model of ischemic stroke. Stroke 42, 770-775.
76. Taguchi, K., Okada, A., Yasui, T., Kobayashi, T., Ando, R., Tozawa, K. & Kohri, K. 2012. Pioglitazone, a peroxisome proliferator activated receptor gamma agonist, decreases renal crystal deposition, oxidative stress and inflammation in hyperoxaluric rats. J Urol 188, 1002-1011.
77. Tanaka, T., Fukunaga, Y., Itoh, H., Doi, K., Yamashita, J., Chun, T.H., Inoue, M., Masatsugu, K., Saito, T., Sawada, N., Sakaguchi, S., Arai, H. & Nakao, K. 2005. Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol 508, 255-265.
78. Troidl, C., Jung, G., Troidl, K., Hoffmann, J., Mollmann, H., Nef, H., Schaper, W., Hamm, C.W. & Schmitz-Rixen, T. 2013. The temporal and spatial distribution of macrophage subpopulations during arteriogenesis. Curr Vasc Pharmacol 11, 5-12.
79. Verrier, E., Wang, L., Wadham, C., Albanese, N., Hahn, C., Gamble, J.R., Chatterjee, V.K., Vadas, M.A. & Xia, P. 2004. PPARgamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase. Circ Res 94, 1515-1522.
80. Vinaixa, M., Rodriguez, M.A., Samino, S., Diaz, M., Beltran, A., Mallol, R., Blade, C., Ibanez, L., Correig, X. & Yanes, O. 2011. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PLoS ONE 6, e29052.
81. Vogel, S., Kubin, T., von der Ahe, D., Deindl, E., Schaper, W. & Zimmermann, R. 2006. MEK hyperphosphorylation coincides with cell cycle shut down of cultured smooth muscle cells. J Cell Physiol 206, 25-34.
82. Wakino, S., Kintscher, U., Kim, S., Yin, F., Hsueh, W.A. & Law, R.E. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1-> S transition in vascular smooth muscle cells. J Biol Chem 275, 22435-22441.
83. Wei-guo, Z., Hui, Y., Shan, L., Yun, Z., Wen-cheng, N., Fu-lin, Y., Fang-yan, F., Jun-hua, G. & Jian-hua, Z. 2010. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways. Immunol Cell Biol 88, 305-312.
84. Werner, C., Kamani, C.H., Gensch, C., Bohm, M. & Laufs, U. 2007. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes 56, 2609-2615.
85. Wohrle, J., Marx, N., Koenig, W., Hombach, V., Kestler, H.A., Hoher, M. & Nusser, T. 2008. Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. Clin Res Cardiol 97, 726-733.
86. Xu, S., Zhao, Y., Yu, L., Shen, X., Ding, F. & Fu, G. 2011. Rosiglitazone attenuates endothelial progenitor cell apoptosis induced by TNF-alpha via ERK/MAPK and NF-kappaB signal pathways. J Pharmacol Sci 117, 265-274.
87. Yun, Z., Maecker, H.L., Johnson, R.S. & Giaccia, A.J. 2002. Inhibition of PPAR gamma 2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev Cell 2, 331-341.
88. Zhang, W.Y., Schwartz, E.A., Permana, P.A. & Reaven, P.D. 2008. Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol 28, 2312-2318.